Description

Erdafitinib Tablets 3 mg

Erdafitinib Tablets 3 mg contain erdafitinib, a prescription targeted therapy used in the treatment of certain advanced cancers with eligible fibroblast growth factor receptor (FGFR) genetic alterations. Erdafitinib belongs to the class of FGFR tyrosine kinase inhibitors, which work by blocking abnormal FGFR signaling pathways involved in the growth and spread of certain cancer cells.

Erdafitinib is approved in some countries for the treatment of adults with locally advanced or metastatic urothelial (bladder) carcinoma that has susceptible FGFR genetic alterations. Approved indications may vary by country, and patients should be tested for eligible FGFR alterations before treatment, according to local prescribing information.

Key Features

• Contains Erdafitinib 3 mg
• Oral tablet formulation
• Targeted FGFR tyrosine kinase inhibitor
• Prescription-only oncology medicine
• Used for selected cancers with eligible FGFR genetic alterations

Uses

Erdafitinib Tablets 3 mg may be prescribed for:

• Locally advanced or metastatic urothelial (bladder) carcinoma with eligible FGFR genetic alterations
• Other approved cancer indications according to local regulatory labeling

How It Works

Erdafitinib inhibits FGFR proteins that can drive the growth and survival of cancer cells with specific genetic alterations. By blocking these signaling pathways, it may help slow disease progression in eligible patients.

Directions for Use

Take Erdafitinib Tablets 3 mg exactly as prescribed by your oncologist. Your dose may be adjusted based on treatment response, laboratory test results, and side effects. Do not stop or change the dose without medical advice.

Possible Side Effects

Common side effects may include:

• Increased phosphate levels in the blood
• Mouth sores
• Dry mouth
• Diarrhea
• Fatigue
• Dry skin
• Nail changes
• Eye or vision problems

Contact your healthcare provider immediately if you develop blurred vision, eye pain, severe skin reactions, persistent diarrhea, or any other serious symptoms.

Precautions

• Use only under the supervision of a qualified oncology specialist.
• Regular blood tests and eye examinations may be required during treatment.
• Inform your healthcare provider about all medicines you take and any existing medical conditions.
• Pregnancy should be avoided during treatment. Follow your healthcare provider’s advice regarding effective contraception.
• Keep out of reach of children.

Storage

Store the tablets at room temperature in their original packaging, protected from moisture and excessive heat. Follow the storage instructions provided by the manufacturer.

Product Information

• Generic Name: Erdafitinib
• Strength: 3 mg
• Dosage Form: Tablet
• Therapeutic Class: Targeted Anticancer Medicine
• Pharmacological Class: FGFR Tyrosine Kinase Inhibitor
• ATC Code: L01EN01
• Prescription Status: Prescription-only medicine
• Primary Indication: Selected advanced cancers with eligible FGFR genetic alterations, according to approved local labeling.